Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
EW vs STE: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
EW Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)
EW Overall Winner
6-Pillar Tally: EW 4 – 2 STE
Matrix Metrics: EW 7 – 3 STE
As of Nov 16, 2026, Edwards Lifesciences Corp (EW) is the stronger overall head-to-head candidate over STERIS plc (STE) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). EW carries a Unified Composite Score of 31.5/100 (SELL) at $106.66 (31.6x Forward P/E, 28.8% operating margin), whereas STE carries 28.1/100 (SELL) at $263.07 (23.9x Forward P/E, 19.2% operating margin).
- Defensive Composite Rating Caution: Although EW compares more favorably head-to-head, both EW (31.5/100 SELL) and STE (28.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About EW vs STE
EW
Head-to-Head Winner
Edwards Lifesciences Corp
$106.66
-0.46% 1D
Market Cap
$60.8B
TTM Revenue
$6.67B
Forward P/E
31.6x
Beta / 30D Vol
0.44β · 24% Vol
Unified Composite Score
31.5
SELL
Tech 50.0
Fund 29.0
Flow 51.0
Mom 44.0
Weinstein Technical Phase
Markup · Hold / add on dips
STE
STERIS plc
$263.07
-0.47% 1D
Market Cap
$24.6B
TTM Revenue
$6.17B
Forward P/E
23.9x
Beta / 30D Vol
0.20β · 37% Vol
Unified Composite Score
28.1
SELL
Tech 50.0
Fund 33.0
Flow 56.0
Mom 40.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (EW 4 – 2 STE)
1. Valuation Multiples
STE
Forward P/E
31.6x
23.9x
Trailing P/E
61.5x
30.4x
PEG Ratio
2.33x
2.50x
EV / Revenue
8.8x
4.2x
2. Growth & Scale
EW
Revenue Growth (YoY)
+10.5%
+8.8%
Earnings Growth (YoY)
+6.7%
+12.9%
TTM Revenue (USD)
$6.67B
$6.17B
Market Cap
$60.8B
$24.6B
3. Profitability & Quality
EW
Gross Margin
78.0%
44.3%
Operating Margin
28.8%
19.2%
Net Profit Margin
15.3%
13.4%
Return on Equity (ROE)
9.3%
11.6%
4. Balance Sheet & Cash Flow
EW
Cash Generation (TTM)
$1.42B
$937M
Cash Flow Margin
21.3%
15.2%
Net Cash / Leverage
$2.41B Net Cash
$1.52B Net Debt (0.28x D/E)
Dividend Yield
None (0.00%)
1.01%
5. Options & Positioning
STE
Options Structure Phase
UNCLASSIFIED
SURGE
Current IV / %ile
24.6% (34th %ile)
32.2% (7th %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markup
ACCUMULATION · Markup
6. R&D & Supply-Chain Moat
EW
OpEx & R&D Intensity
49.2% of Rev ($3.28B)
25.1% of Rev ($1.55B)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Scale & Operating Efficiency Moat
Scale & Operating Efficiency Moat
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: EW (7) vs STE (3)| Institutional Metric | EW | STE | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $60.8B | $24.6B | EW | |
| Trailing P/E Ratio | 61.5x | 30.4x | STE | |
| Forward P/E Ratio | 31.6x | 23.9x | STE | |
| Revenue Growth (YoY) | +10.5% | +8.8% | EW | |
| Operating Margin (TTM) | 28.8% | 19.2% | EW | |
| Net Profit Margin | 15.3% | 13.4% | EW | |
| Return on Equity (ROE) | 9.3% | 11.6% | STE | |
| 52-Week Range Position | 96% ($75–$108) | 91% ($195–$269) | EW | |
| Beta / 30D Volatility | 0.44β · 24% Vol | 0.20β · 37% Vol | EW | |
| Unified Institutional Score | 31.5 / 100 (SELL) | 28.1 / 100 (SELL) | EW | |
| Trailing 12M Revenue (USD) | $6.67B | $6.17B | Scale | |
| Gross Profit Margin (TTM) | 78.0% | 44.3% | Quality | |
| PEG Ratio & EV / Revenue | 2.33x PEG · 8.8x EV/Rev | 2.50x PEG · 4.2x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $1.42B ($2.41B Net Cash) | $937M ($1.52B Net Debt (0.28x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
EW +5.01 pp
3M Horizon
EW +4.03 pp
6M Horizon
EW +5.87 pp
1Y Horizon
EW +22.85 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | EW Revenue | STE Revenue | EW Op. Margin | STE Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $4.35B | $2.78B | 26.4% | 14.8% | EW |
| FY2020 | $4.39B | $3.03B | 20.5% | 17.7% | EW |
| FY2021 | $5.23B | $3.11B | 32.3% | 17.6% | EW |
| FY2022 | $4.46B | $4.22B | 33.6% | 11.3% | EW |
| FY2023 | $5.01B | $4.54B | 26.1% | 17.4% | EW |
| FY2024 | $5.44B | $5.14B | 25.3% | 16.3% | EW |
| FY2025 | $6.07B | $5.46B | 20.8% | 15.9% | EW |
| FY2026 | N/A | $5.94B | N/A | 18.6% | STE |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
EW
UNCLASSIFIED
Current IV
24.6%
IV Percentile
34th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact EW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
STE
SURGE
Current IV
32.2%
IV Percentile
7th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact STE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
EW Moat Profile
Scale & Operating Efficiency Moat
Medical Devices Operator
OpEx & R&D Reinvestment
49.2% of Rev ($3.28B)
90D Engineering Disclosures
0 Published
STE Moat Profile
Scale & Operating Efficiency Moat
Medical Devices Operator
OpEx & R&D Reinvestment
25.1% of Rev ($1.55B)
90D Engineering Disclosures
0 Published
Investor FAQ EW vs STE Key Questions & Quantitative Answers
As of Nov 16, 2026, Edwards Lifesciences Corp (EW) is the stronger overall head-to-head candidate over STERIS plc (STE) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). EW carries a Unified Composite Score of 31.5/100 (SELL) at $106.66 (31.6x Forward P/E, 28.8% operating margin), whereas STE carries 28.1/100 (SELL) at $263.07 (23.9x Forward P/E, 19.2% operating margin). Defensive Composite Rating Caution: Although EW compares more favorably head-to-head, both EW (31.5/100 SELL) and STE (28.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
EW leads the Growth & Scale pillar: EW posts +10.5% YoY revenue growth and +6.7% YoY earnings growth on $6.67B TTM revenue (78.0% gross margin, 28.8% operating margin), compared with STE at +8.8% YoY revenue growth and +12.9% YoY earnings growth on $6.17B TTM revenue (44.3% gross margin, 19.2% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), EW cumulative revenue shifted +39.5% while STE shifted +113.7%. In operating R&D and SG&A reinvestment, EW deploys 49.2% of Rev ($3.28B) (0 90-day corporate R&D disclosures) versus 25.1% of Rev ($1.55B) (0 disclosures) for STE.
STE screens cheaper on headline valuation multiples. EW trades at 31.6x Forward P/E, 61.5x Trailing P/E, 2.33x PEG, and 8.8x EV/Revenue (21.3% FCF margin), whereas STE trades at 23.9x Forward P/E, 30.4x Trailing P/E, 2.50x PEG, and 4.2x EV/Revenue (15.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EW (9.3% ROE) versus STE (11.6% ROE) capital efficiency.
In options market volatility and institutional positioning, EW carries 24.6% implied volatility (34th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.44β · 24% Vol realized risk). By comparison, STE carries 32.2% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (0.20β · 37% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
STE vs EW · Reverse Pair
EW vs BAX
· Sector Peer
EW vs BSX
· Sector Peer
EW vs RMD
· Sector Peer
STE vs TFX
· Sector Peer
STE vs COO
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem